Immucell Corp /de/ (Nasdaq: ICCC), an SEC filer in In Vitro & In Vivo Diagnostic Substances, closed at $9.94, -0.8%, on 2026-08-28, with a market cap of $90M, a return on equity of -3.8%, a net margin of -3.8% and 3-year sales growth of 14.2%. Institutional ownership, earnings history and filed financials are on the tabs below.
Returns use ADJUSTED closes (splits + dividends).
Volume as VALUE TRADED — close × volume, in USD.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | ICCC | SPY | Δ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 · ytd | −2.1% | +9.1% | −3.7% | +33.6% | +17.0% | +1.5% | +11.5% | −11.3% | — | — | — | — | +61.6% | +13.4% | +48.2pp |
| 2025 | +4.8% | −2.1% | −9.3% | +13.2% | +18.1% | +8.7% | −8.5% | +0.5% | −2.3% | −0.2% | −22.4% | +27.1% | +19.4% | +17.7% | +1.7pp |
| 2024 | +4.3% | −0.6% | +0.4% | −7.4% | −13.4% | +14.1% | −16.3% | −7.9% | −2.9% | −0.6% | +14.1% | +25.0% | +1.2% | +24.9% | −23.7pp |
| 2023 | +21.7% | −20.5% | −12.5% | −4.7% | −3.0% | +4.8% | +8.6% | −15.1% | +15.8% | −5.4% | −10.1% | +12.1% | −16.6% | +26.2% | −42.7pp |
| 2022 | +1.9% | +0.2% | +18.1% | +0.9% | −16.7% | +7.2% | +1.0% | −17.0% | +2.6% | +7.1% | −13.9% | −11.6% | −23.8% | −18.2% | −5.6pp |
| 2021 | +57.1% | +12.5% | −8.4% | +12.7% | −10.0% | −2.8% | +6.0% | −9.0% | +2.2% | −6.0% | +1.5% | −10.4% | +34.5% | +28.7% | +5.7pp |
| 2020 | +4.1% | +7.3% | −34.1% | +20.6% | −1.4% | +4.9% | +5.3% | +4.8% | +4.0% | −2.2% | +17.3% | −4.5% | +15.5% | +18.3% | −2.8pp |
| 2019 | +11.5% | −8.1% | −12.1% | +1.3% | −4.1% | +5.4% | −7.4% | −10.3% | +3.1% | −7.4% | −3.0% | +3.0% | −26.9% | +31.2% | −58.1pp |
| 2018 | −16.7% | −1.2% | −3.2% | +3.0% | −2.5% | −3.0% | −0.3% | +2.5% | +19.5% | −4.2% | −7.9% | −4.1% | −19.8% | −4.6% | −15.3pp |
| 2017 | −0.5% | −5.2% | −1.4% | −1.6% | +13.6% | +18.6% | −6.5% | −15.2% | +11.9% | +21.5% | +13.8% | −2.2% | +47.7% | +21.7% | +26.0pp |
Month-end over prior month-end; a blank cell is no return.
Basis. Both columns share one basis, so Δ is like-for-like.
End-of-day closes; a “ytd” or “part” year is not a full year.
| Month | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Years ⓘ | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 22 | 21 | 21 | 21 | 21 |
| Positive ⓘ | 67% | 43% | 48% | 57% | 52% | 81% | 43% | 45% | 67% | 24% | 38% | 43% |
| Median | +1.9% | −1.2% | −1.3% | +1.3% | +0.2% | +4.9% | −0.6% | −5.9% | +3.5% | −2.2% | −3.0% | −0.8% |
| Best | +57.1% | +13.5% | +37.7% | +35.0% | +18.1% | +78.3% | +40.1% | +22.7% | +22.2% | +21.5% | +17.3% | +27.1% |
| Worst | −22.1% | −23.3% | −34.1% | −14.6% | −16.7% | −10.1% | −33.1% | −34.0% | −20.9% | −27.7% | −22.4% | −15.3% |
| vs SPY ⓘ | +3.5pp | −1.7pp | −1.6pp | −1.8pp | −1.5pp | +3.1pp | −4.0pp | −7.3pp | +6.8pp | −2.5pp | −6.7pp | −0.4pp |
253 monthly observations · 2005–2026 · benchmark SPY
